U.S. FDA Approves Expanded Label for Astellas’ IZERVAY for Geographic Atrophy
February 13, 2025
Astellas Pharma, announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY for the treatment of geographic atrophy (GA) secondary